Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

被引：9

作者：

Damm-Welk, Christine ^{[1
,2
]}

Siddiqi, Faraz ^{[3
]}

Fischer, Matthias ^{[4
,5
,6
]}

Hero, Barbara ^{[4
]}

Narayanan, Vignesh ^{[7
]}

Camidge, David Ross ^{[7
]}

Harris, Michael ^{[3
]}

Burke, Amos ^{[8
]}

Lehrnbecher, Thomas ^{[9
]}

Pulford, Karen ^{[10
]}

Oschlies, Ilske ^{[11
]}

Siebert, Reiner ^{[12
,13
]}

Turner, Suzanne ^{[3
]}

Woessmann, Wilhelm ^{[1
,2
]}

机构：

[1] Univ Giessen, NHL BFM Study Ctr, Giessen, Germany

[2] Univ Giessen, Dept Paediat Haematol & Oncol, Feulgenstr 12, D-35392 Giessen, Germany

[3] Univ Cambridge, Dept Pathol, Cambridge, England

[4] Univ Cologne, Dept Paediat Haematol & Oncol, Cologne, Germany

[5] Univ Cologne, Fac Med, Ctr Mol Med Cologne, Cologne, Germany

[6] Max Planck Inst Metab Res, Cologne, Germany

[7] Univ Colorado, Ctr Canc, Aurora, CO USA

[8] Addenbrookes Hosp, Dept Paediat Oncol, Cambridge, England

[9] Goethe Univ Frankfurt, Dept Paediat Haematol & Oncol, Frankfurt, Germany

[10] Univ Oxford, Nuffield Div Clin Lab Sci, Oxford, England

[11] Univ Kiel, Dept Pathol, Kiel, Germany

[12] Univ Kiel, Inst Human Genet, Campus Kiel, Kiel, Germany

[13] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

来源：

JOURNAL OF CANCER | 2016年 / 7卷 / 11期

基金：

英国惠康基金;

关键词：

ALK-antibody titre; NSCLC; neuroblastoma; lymphoma; ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; LUNG-CANCER; TYROSINE KINASE; NEUROBLASTOMA; GENE; FEATURES; DISEASE; ALCL; IDENTIFICATION;

D O I：

10.7150/jca.15238

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.

引用

页码：1383 / 1387

页数：5

共 25 条

[1] Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk [J].